Crown CRO

ELPEN is the leading Greek pharmaceutical company.
With more than 850 employees, the company ranks 6th among more than 400 companies in the Greek market, with an annual turnover of €150 million (IMS data).

ELPEN has been active in export activities since 1990, with an international presence in more than 60 countries worldwide and a subsidiary in Berlin, Germany, since 2009.
We specialize in branded generics and originator products in CVS, CNS, respiratory, oncology and antimicrobials.

Elpen’s activities include product development, production, regulatory affairs, marketing, sales, and exports. R&D is performed in 1.000m2 facilities focusing on cardiology, endocrinology, cancer, respiratory diseases and OTC. Examples of R&D activities include the Elpenhaler® DPI products already introduced in the EU markets, such as Formopen® (formoterol), Fluticapen® (fluticasone) and Rolenium® (salmeterol/fluticasone combination). We possess full production lines of Oral Solids, Oral Liquids, Dry Powder Inhalation, Injectable, Lyophilized products and a dedicated facility for the production of Oral Solid Penicillin.

Qualitis Ltd, is a Full-Service Clinical Research and Medical Consulting Organization based in Greece and offering a comprehensive portfolio of clinical development and medical consulting services to the Pharmaceutical, Biotechnology and Medical Device industries.

Through a commitment to a Company culture of superior quality service, integrity and innovation, Qualitis focuses on exceeding its customers particular needs and expectations.

Qualitis Team possesses an in-depth and long-term experience and expertise in both clinical research and medical-marketing environment and is strongly dedicated in constant learning and continuous improvement driven to create added value for our customers and become an integral part of their business success.

With a strong focus on people and standards, Qualitis has built upon the 3 milestones of business success: Quality, Commitment and Customer Trust.

Our specialty areas include but are not limited to the following:
-Cardiovascular diseases
-Neurology & Psychiatry
-Pulmonary/Respiratory
-Genitourinary
-Gastroenterology
-Oncology
-Orthopedics
-Pediatrics
-Biotechnology
-Allergy/Immunology
-Dermatology
-Virology
-Endocrinology
-Hematology
-Ophthalmology

Areas of Operation-Projects Portfolio:
-Phase II-IV Clinical Trials
-Medical Device Studies
-Non-Interventional Studies
-Pharmacovigilance Studies
-IIS (Investigator Initiated Studies)
-Epidemiological Studies
-Market Surveys

Customers Profile:
-Pharmaceutical Companies
-Biotechnology Companies
-Medical Devices Companies
-Academic Research Institutes & Hospitals
-International CROs

Contact Details: E-mail: info@qualitis.gr
Telephone: +30 210-7797750
Fax: +30 210-7470441

Taros Chemicals GmbH & Co. KG, an independent, privately owned contract research organization based in Dortmund, Germany, has been serving the chemistry needs of pharmaceutical, chemical and biotech companies since its inception in 1999. A forerunner in the early German biotech scene, Taros can claim more than 13,000 syntheses, research and process chemistry projects delivered to-date to an increasingly expanding and diverse base of global customers.

In its state-of-the-art facilities in Dortmund's prestigious BioMedizinZentrum (BMZ), the hub of top ranking biotech organizations, Taros'​ team of highly creative and skilled scientists, aided by its state-of-the-art laboratory facilities, are wholly committed to solving a wide range of customers'​ R&D problems in innovative drug discovery, medicinal chemistry and classical synthetic chemistry. Their collective knowledge and experience in industrial organic chemistry, span a period of over 160 years, and in active drug discovery, around 60 years, covering the full spectrum, from big pharma to biotechnology. Taros is active today in therapeutic areas which include oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious diseases, in all small-molecule target classes.

Our company's mission is to enhance the quality of human lives by providing advanced and innovative chemistry-driven technologies to our customers R&D endeavors in the global marketplace. We strive hard to provide creative, holistic and cost-effective solutions with the highest level of quality, reliability and integrity. We continuously endorse loyalty and commitment in our employees, inspiring them to provide exceptional value to our customers'​ R&D processes, by anticipating hurdles before they arise, by foreseeing potential cost and lead time reductions, and most importantly, by facilitating their competitive and "early to market"​ advantage.

Accell Clinical Research is an international full-service Contract Research Organization (CRO) managing Phase I-III clinical trials for 10+ years across Eastern Europe. With local presence, including highly qualified medical staff and legal entities in the region, we successfully recruit patients both in EU and outside EU in post-Soviet countries (CIS). All together we provide guaranteed fast patient recruitment in 20+ countries across the region.

⬇︎ ACCELL'S SERVICES for Phase I-III clinical trials:

• Strategic guidance and trial set-up:
• Feasibility research and site selection
• Study documentation development
• Regulatory support
• Clinical supply import and management
• Selection and management of clinical study vendors
• Project management
• Clinical & medical monitoring
• Data management and biostatistics
• Quality assurance
• Safety management
• TMF/eTMF services
• Functional outsourcing of a clinical team

⬇︎ THERAPEUTIC AREAS
• Oncology
• Cardiovascular
• Immunology
• Gastroenterology
• Neurology
• Endocrinology

Founded in 1997, Ergomed plc is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with a strong heritage in the development of drugs in rare diseases and oncology.

• 1 300+ highly qualified professionals
• Global full-service CRO
• 24+ years of experience
• Therapeutic specialization in oncology
• Strong expertise in rare disease trials
• Robust clinical safety system
• Choice of leading drug safety databases

Our key services include:
• Clinical Research Services
• Pharmacovigilance
• Medical Information
• Regulatory
• Medical Writing
• Site Management
• Study Physician Support
• Biostatistics
• Patient Study Support